Stem Cell Treatment Efficacy
A single stem cell infusion led to a 94% reduction in fragility fractures over 2 years in a small study of 10 women with advanced osteoporosis.
Weight Loss Medications
Novo Nordisk’s low-dose investigational CagriSema outperformed Tirzepatide for weight loss (12.4% vs 9.1%) in a phase III trial of adults with type 2 diabetes.
Meanwhile, Roche’s investigational dual agonist enicepatide led to a 15.5% weight loss at 48 weeks in a phase II trial of adults with obesity and diabetes.
Testosterone Therapy Assessment
The FDA convened an expert panel to evaluate the evidence for testosterone therapy for menopausal women.
After a brief pause, the Pentagon will continue its controversial program to test troops’ testosterone levels.
Cognitive Decline and Bone Density
Deep learning analysis of noncontrast chest CTs linked lower thoracic vertebral bone mineral density (BMD) with faster cognitive decline, particularly in adults with diabetes.
Legal Developments in Gender-Affirming Care
The Justice Department announced that New York University Langone Hospitals and the University of Pittsburgh Medical Center agreed to stop providing gender-affirming care for minors, resulting in over $9 million in fines.
Risks Associated with GLP-1 Drugs
Dozens of patients have sued GLP-1 drug manufacturers, claiming they were not adequately warned about the risk of non-arteritic anterior ischemic optic neuropathy, a rare type of sudden vision loss.
Health Insurance Adjustments
Employer-sponsored health insurance plans are expected to adjust their coverage of GLP-1 drugs.
Diabetes Management Insights
A real-world study of 246 adults with type 1 diabetes linked worsening time-in-target glucose range to a higher 5-year incidence of microvascular complications.
Illinois Gov. JB Pritzker, who has diabetes and has long struggled with his weight, stated he lost 80 pounds after using a GLP-1 medication.
SGLT2 inhibitors and GLP-1 drugs significantly reduced the risk of renal function decline compared with DPP-4 inhibitors in a target trial emulation of adults with type 2 diabetes and albuminuria.
Disclaimer: The information provided is for educational purposes only and should not be considered a substitute for professional medical advice or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Fuente: https://www.medpagetoday.com/endocrinology/generalendocrinology/123105
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
